Optimizing antibiotic pharmacodynamics in hospital-acquired and ventilator-acquired bacterial pneumonia

Clinics in Chest Medicine

Volumn 32, Issue 3, 2011, Pages 439-450

  Housman, Seth T ^a   Kuti, Joseph L ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

Hospital acquired pneumonia; Monte carlo simulation; Pharmacodynamics; Ventilator acquired pneumonia

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CREATININE; DORIPENEM; ERTAPENEM; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; OXAZOLIDINONE DERIVATIVE; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN; VANCOMYCIN;

ACINETOBACTER; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; BACTERIAL PNEUMONIA; CAPILLARY LEAK SYNDROME; CENTRAL NERVOUS SYSTEM DISEASE; COMMUNITY ACQUIRED PNEUMONIA; CONTINUOUS INFUSION; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DISTRIBUTION VOLUME; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; ESCHERICHIA COLI; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; INFECTION; INTENSIVE CARE; KLEBSIELLA; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; PHARMACODYNAMICS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT INFECTION; REVIEW; STAPHYLOCOCCAL PNEUMONIA; UNSPECIFIED SIDE EFFECT; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-BACTERIAL AGENTS; HUMANS; MONTE CARLO METHOD; PNEUMONIA, BACTERIAL; PNEUMONIA, VENTILATOR-ASSOCIATED;

EID: 80051884221     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2011.05.006     Document Type: Review

References (64)

1. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-acquired, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005, 171:388-416.
2. Kieninger A.N., Lipsett P.A. Hospital-acquired pneumonia: pathophysiology, diagnosis, and treatment. Surg Clin North Am 2009, 89:439-461.
3. Rello J., Sa-Borges M., Correa H., et al. Variations in etiology of ventilator-associated pneumonia across four treatment sites: implications for antimicrobial prescribing practices. Am J Respir Crit Care Med 1999, 160:608-613.
4. Chastre J., Fagon J.Y. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002, 165:867-903.
5. Rello J., Ollendorf D.A., Oster G., et al. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest 2002, 122:2121.
6. Fagon J.Y., Chastre J., Hance A.J., et al. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med 1993, 94:281-288.
7. AHRQ News and Numbers. Pneumonia most common reason for hospitalization 2008. Agency for healthcare research and quality, Rockville (MD). Available at: Accessed December 12, 2010. http://www.ahrq.gov/news/nn/nn070208.htm.
8. Kollef M.H., Shorr A., Tabak Y.P., et al. Epidemiology and outcomes of health-care associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005, 128:3854-3862.
9. Weber D.J., Rutala W.A., Sickbert-Bennett E.E., et al. Microbiology of ventilator-associated pneumonia compared with that of hospital-acquired pneumonia. Infect Control Hosp Epidemiol 2007, 28(7):825-831.
10. Jones R.N. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis 2010, 51(S1):S81-S87.
11. Gillespie E.L., Kuti J.L., Nicolau D.P. When " S" doesn't mean success: the importance of choice of antibiotic and dose on clinical and economic outcomes of severe infections. Conn Med 2005, 69:203-210.
12. Varghese J.M., Roberts J.A., Lipman J. Antimicrobial pharmacokinetic and pharmacodynamic issues in the critically ill with severe sepsis and septic shock. Crit Care Clin 2011, 27:19-34.
13. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rational for antibacterial dosing of mice and men. Clin Infect Dis 1998, 26:1-10.
14. Turnidge J.D. The pharmacodynamics of β-lactams. Clin Infect Dis 1998, 27:10-22.
15. Drusano G.L. Antimicrobial pharmacodynamics: critical interactions of " bug and drug" Nat Rev Microbiol 2004, 2:289-300.
16. Bochud P.Y., Calandra T. Pathogenesis of sepsis: new concepts and implications for future treatment. BMJ 2003, 326:262-266.
17. Glauser M.P., Zanetti G., Baumgartner J.D., et al. Septic shock. Pathogenesis Lancet 1991, 338(8769):732-736.
18. Buerger C., Plock N., Dehghanyar P., et al. Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis. Antimicrob Agents Chemother 2006, 50(7):2455-2463.
19. Joukhadar C., Frossard M., Mayer B.X., et al. Impaired target site penetration of beta-lactams may account for therapeutic failure in patients with septic shock. Crit Care Med 2001, 29(2):385-391.
20. Ulldemolins M., Roberts J.A., Rellow J., et al. The effects of hypoalbuminemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet 2011, 50(2):99-110.
21. Fleck A., Raines G., Hawker F., et al. Increased vascular permeability: a major cause of hypoalbuminemia in disease and injury. Lancet 1985, 1(8432):781-784.
22. Taccone F.S., Laterre P.F., Dugernier T., et al. Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care 2010, 14(4):R126.
23. Roberts J.A., Roberts M.S., Roberston T.A., et al. Piperacillin penetration into tissue of critically ill patients with sepsis-bolus versus continuous administration?. Crit Care Med 2009, 37(3):926-933.
24. Meagher A.K., Forrest A., Rayner C.R., et al. Population pharmacokinetics of linezolid in patients treated in a compassionate-use program. Antimicrob Agents Chemother 2003, 47(2):548-553.
25. Ong C.R., Tessier P.R., Li C., et al. Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps. Diagn Microbiol Infect Dis 2007, 57:153-161.
26. Mattoes H.M., Kuti J.L., Drusano G.L., et al. Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem. Clin Ther 2004, 26:1189-1198.
27. Li J., Turnidge J., Milne R., et al. In vitro pharmacodynamic properties of colistin methanesulfonate against Pseudomonas aeruginosa isolate from patients with cystic fibrosis. Antimicrob Agents Chemother 2001, 45:781-785.
28. Moore R.D., Smith C.R., Lietman P.S. The association of aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987, 155:93-99.
29. Preston S.L., Drusano G.L., Berman A.L., et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 1998, 279:125-129.
30. Crandon J.L., Bulik C.C., Kuti J.L., et al. Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa. Antimicrob Agents Chemother 2010, 54(3):1111-1116.
31. Andes D., van Ogtrop M.L., Pen J., et al. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob Agents Chemother 2002, 46(11):3484-3489.
32. Rayner C.R., Forrest A., Meager A.K., et al. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet 2003, 42(15):1411-1423.
33. Liu C., Bayer A., Cosgrove S.E., et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011, 52:1-38.
34. Moise-Broder P.A., Forrest A., Birmingham M.C., et al. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004, 43(13):925-942.
35. Moore R.D., Smith C.R., Lietman P.S. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis 1984, 149:443-448.
36. Freeman C.D., Nicolau D.P., Belliveau P.P., et al. Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. J Antimicrob Chemother 1997, 39:677-686.
37. Nicolau D.P., Freeman C.D., Belliveau P.P., et al. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother 1995, 39:650-655.
38. Kashuba A.D., Nafziger A.N., Drusano G.L., et al. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother 1999, 43(3):623-629.
39. Ambrose P.G., Grasela D.M., Grasela T.H., et al. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 2001, 45(10):2793-2797.
40. Forrest A., Nix D.E., Ballow C.H., et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993, 37:1073-1081.
41. Thomas J.K., Forrest A., Bhavnani S.M., et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998, 42:521-527.
42. Shentag J.J. Clinical pharmacology of fluoroquinolones: studies in human dynamic/kinetic models. Clin Infect Dis 2000, 31(Suppl 2):S40-S44.
43. Zelenitsky S.A., Ariano R.E., Zhanel G.G. Pharmacodynamics of empirical antibiotic monotherapies for an intensive care unit (ICU) population based on Canadian surveillance data. J Antimicrob Chemother 2011, 66(2):343-349.
44. Nicasio A.M., Ariano R.E., Zelenitsky S.A., et al. Population pharmacokinetics of high-dose, prolonged infusion cefepime in adult critically ill patients with ventilator-associated pneumonia. Antimicrob Agents Chemother 2009, 53(4):1476-1481.
45. Drusano G.L. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis 2003, 36(Suppl 1):S42-S50.
46. Patel N., Scheetz M.H., Drusano G.L., et al. Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients. Antimicrob Agents Chemother 2010, 54(1):460-465.
47. Nicolau D.P. Pharmacokinetic and pharmacodynamic properties of meropenem. Clin Infect Dis 2008, 47:S32-S40.
48. Roberts J.A., Kirkpatrick C.M., Lipman J. Monte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients. J Antimicrob Chemother 2011, 66:227-231.
49. Koomanachai P., Bulik C.C., Kuti J.L., et al. Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States. Clin Ther 2010, 32(4):766-779.
50. Sun H.K., Kuti J.L., Nicolau D.P. Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA program. Crit Care Med 2005, 33(10):2222-2227.
51. Kim A., Kuti J.L., Nicolau D.P. Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia. Clin Ther 2009, 31(11):2765-2778.
52. Crandon J.L., Kuti J.L., Jones R.N., et al. Comparison of 2002-2006 OPTAMA programs for US hospitals: focus on gram-negative resistance. Ann Pharmacother 2009, 43(2):220-227.
53. Lodise T.P., Lomaestro B., Drusano G.L. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007, 44:357-363.
54. Georges B., Conil J.M., Cougot P., et al. Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen. Int J Clin Pharmacol Ther 2005, 43:360-369.
55. Roos J.F., Bulitta J., Lipman J., et al. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units. J Antimicrob Chemother 2006, 58:987-993.
56. Crandon J.L., Ariano R.E., Zelenitsky S.A., et al. Optimization of meropenem dosage in the critically ill population based on renal function. Intensive Care Med 2011, 37(4):632-638.
57. Deryke C.A., Kuti J.L., Nicolau D.P. Re-evaluation of current susceptibility breakpoints for gram-negative rods based on pharmacodynamic assessment. Diagn Microbiol Infect Dis 2007, 58:337-344.
58. Benko R., Matuz M., Doro P., et al. Pharmacokinetics and pharmacodynamics of levofloxacin in critically ill patients with ventilator-associated pneumonia. Int J Antimicrob Agents 2007, 30(2):162-168.
59. Shorr A.F., Zadeikis N., Xiang J.X., et al. A multi-center, randomized, double-blind, retrospective comparison of 5- and 10-day regimens of levofloxacin in a subgroup of patients aged >or = 65 years with community-acquired pneumonia. Clin Ther 2005, 27(8):1251-1259.
60. Lorente L., Jimenez A., Palermo S., et al. Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusions: a retrospective, nonrandomized, open-label, historical chart review. Clin Ther 2007, 29(11):2433-2439.
61. Lorente L., Lorenzo L., Martin M.M., et al. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli. Ann Pharmacother 2006, 40:219-223.
62. Lorente L., Jiminez A., Martin M.M., et al. Clinical cure of ventilator-associated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion. Int J Antimicrob Agents 2009, 33(5):464-468.
63. Nicasio A.M., Eagye K.J., Nicolau D.P., et al. Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia. J Crit Care 2010, 25(1):69-77.
64. Nicasio A.M., Eagye K.J., Kuti E.L., et al. Length of stay and hospital costs associated with a pharmacodynamic-based clinical pathway for empiric antibiotic choice for ventilator-associated pneumonia. Pharmacotherapy 2010, 30(5):453-462.